Mylan and Pfizer will divest some assets and abide by other conditions to settle antitrust concerns by the Federal Trade Commission over Mylan’s pending acquisition of Pfizer’s Upjohn unit.
The FTC cited seven generic drug markets in the U.S. in which the combination of Mylan and Upjohn would harm competition by reducing the number of suppliers.
Under the settlement, Mylan will sell the rights and assets related to its eplerenone tablets, a diuretic, to privately held Prasco LLC, which is based in Ohio.
Upjohn will sell the rights and assets related to six medications to Prasco: amlodipine besylate/atorvastatin calcium tablets, which treat high blood pressure and high cholesterol; phenytoin chewables used to prevent epileptic seizures; prazosin HCI capsules for high blood pressure; spironolactone HCTZ tablets, a diuretic; gatifloxacin solution, an eye drop for infections; and medroxyprogesterone acetate injections used to treat uterine bleeding.
Terms also require Mylan, Upjohn or the combined company to get approval from the FTC before gaining any additional interest in three products: levothyroxine sodium tablets, which treat hypothyroidism; sucralfate tablets used to treat and prevent ulcers; and varenicline tartrate tablets offered under the Chantix brand, which help people stop smoking.
After a 30-day public comment period, the FTC will decide whether to make the settlement final.
The merger of Mylan and Upjohn — Pfizer’s generic and off-patent brand-name drug unit — is set to be completed Nov. 16. The combined company will be called Viatris.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.